Robert Mauch Sells 5,096 Shares of Cencora (NYSE:COR) Stock

Cencora, Inc. (NYSE:COR) CEO Robert Mauch sold 5,096 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Cencora Stock Performance

Shares of COR stock opened at $353.07 on Friday. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The firm has a 50-day moving average of $348.49 and a 200-day moving average of $321.90. Cencora, Inc. has a one year low of $237.71 and a one year high of $377.54. The company has a market cap of $68.49 billion, a P/E ratio of 44.41, a P/E/G ratio of 1.68 and a beta of 0.66.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the previous year, the company earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were given a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Institutional Investors Weigh In On Cencora

Several institutional investors have recently made changes to their positions in the stock. Bridgewater Advisors Inc. raised its stake in shares of Cencora by 7.4% during the 4th quarter. Bridgewater Advisors Inc. now owns 1,403 shares of the company’s stock valued at $474,000 after purchasing an additional 97 shares during the period. Farther Finance Advisors LLC grew its holdings in Cencora by 133.0% during the 4th quarter. Farther Finance Advisors LLC now owns 6,242 shares of the company’s stock valued at $2,108,000 after buying an additional 3,563 shares in the last quarter. Sage Mountain Advisors LLC increased its position in shares of Cencora by 41.0% during the fourth quarter. Sage Mountain Advisors LLC now owns 1,110 shares of the company’s stock valued at $375,000 after buying an additional 323 shares during the period. LOM Asset Management Ltd increased its position in shares of Cencora by 11.0% during the fourth quarter. LOM Asset Management Ltd now owns 11,373 shares of the company’s stock valued at $3,841,000 after buying an additional 1,129 shares during the period. Finally, Optima Capital LLC purchased a new stake in shares of Cencora in the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on COR. Barclays began coverage on shares of Cencora in a research report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price objective on the stock. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday. TD Cowen increased their price objective on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Robert W. Baird set a $415.00 target price on Cencora in a research note on Tuesday, January 13th. Finally, JPMorgan Chase & Co. upped their price target on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $393.08.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.